Okami Medical Secures $45M, Names New CEO for Growth
December 3, 2025, 3:33 pm
Location: United States, California, Menlo Park
Employees: 11-50
Founded date: 1981
Okami Medical, a vascular tech firm, closed a $45M round. The funding will fuel expansion and innovation. Drew Hykes, ex-Inari Medical CEO, now leads Okami. Gilde Healthcare led the round, joining the board.
Okami Medical, a California-based innovator in vascular embolization, just landed $45 million in funding. This investment will drive the company's expansion and development of its medical devices. The company also appointed a new CEO to lead this next phase.
The funding round was spearheaded by Gilde Healthcare. Vensana Capital and U.S. Venture Partners, existing investors, also participated. Geoff Pardo and Susana Amorim, from Gilde Healthcare, are now on Okami's Board of Directors.
Okami Medical plans to use the money to grow its sales force. Clinical programs will also see advancement. The company aims to further develop its technology.
Drew Hykes is the new President and CEO. He previously led Inari Medical. Bill Hoffman is the new Chairman of the Board.
Okami Medical focuses on devices for occluding peripheral vessels. The company was founded in 2017 by Inceptus Medical.
Gilde Healthcare expressed confidence in Okami's technology. They see a large market opportunity. Gilde previously collaborated with Hykes at Inari Medical. This new partnership signals strong belief in Okami's future.
The LOBO vascular occluder is a key product. It is designed to stop blood flow in targeted areas. Okami aims to improve patient outcomes in vascular disease.
Okami's devices are intended to be user-friendly. They aim to offer versatility for various medical situations. The company's goal is to restore patient health through advanced technology.
This funding and leadership change marks a pivotal moment for Okami. They are poised for significant growth. The company seeks to improve vascular disease treatment. They will achieve this through commercial expansion. They will also develop new innovations.
The investment underscores confidence in Okami's technology. The market for vascular embolization solutions is growing. Okami is positioning itself to be a leader in this space.
The company's focus on patient outcomes is a key differentiator. Their devices are designed with both physicians and patients in mind. This patient-centric approach resonates with investors.
Okami's leadership team has a proven track record. Drew Hykes' experience at Inari Medical is invaluable. Bill Hoffman's expertise will guide the company's strategic direction.
The new board members from Gilde Healthcare bring significant experience. Their insights will help Okami navigate the medical technology landscape.
Okami's location in California's medical technology hub is advantageous. They have access to talent and resources. This supports innovation and growth.
The company's commitment to innovation is ongoing. They are developing new devices to meet evolving medical needs. This ensures they remain competitive.
Okami's growth strategy involves expanding its commercial reach. They plan to increase adoption of their LOBO platform. They also aim to broaden their product portfolio.
The $45 million funding round provides Okami with the resources. They need to execute their growth plans. They will strengthen their market position.
Okami Medical is targeting a significant unmet need in vascular care. Their technology has the potential to improve patient outcomes. It will streamline medical procedures.
The company's story is one of innovation, strategic leadership, and financial backing. This puts them on a path to success. They are poised to make a lasting impact on healthcare.
The vascular embolization market is expected to grow. This growth is driven by an aging population. There are also technological advancements. Okami Medical is well positioned to capitalize on this trend. They are solving a growing medical issue.
Okami's versatile devices are suited for a variety of vascular anatomies. This versatility gives them a competitive advantage. They can address a broader range of medical cases.
The company's focus on clinical programs demonstrates their commitment. They are dedicated to proving the effectiveness of their technology. This builds trust with physicians and patients.
The appointment of Drew Hykes as CEO is a strategic move. His experience in scaling medical device companies is invaluable. He will lead Okami through its next phase of growth.
The addition of Geoff Pardo and Susana Amorim to the board provides valuable expertise. They have a proven track record in the medical technology sector. This will guide Okami's strategic decisions.
Okami Medical's future looks bright. They are well-funded, well-led, and focused on a growing market. They will make a significant impact on vascular care.
The company's innovative solutions are transforming patient treatment. They are improving outcomes for those with vascular disease.
Okami Medical is set to become a key player in the medical device industry. They will lead innovation in vascular embolization.
"
Okami Medical, a California-based innovator in vascular embolization, just landed $45 million in funding. This investment will drive the company's expansion and development of its medical devices. The company also appointed a new CEO to lead this next phase.
The funding round was spearheaded by Gilde Healthcare. Vensana Capital and U.S. Venture Partners, existing investors, also participated. Geoff Pardo and Susana Amorim, from Gilde Healthcare, are now on Okami's Board of Directors.
Okami Medical plans to use the money to grow its sales force. Clinical programs will also see advancement. The company aims to further develop its technology.
Drew Hykes is the new President and CEO. He previously led Inari Medical. Bill Hoffman is the new Chairman of the Board.
Okami Medical focuses on devices for occluding peripheral vessels. The company was founded in 2017 by Inceptus Medical.
Gilde Healthcare expressed confidence in Okami's technology. They see a large market opportunity. Gilde previously collaborated with Hykes at Inari Medical. This new partnership signals strong belief in Okami's future.
The LOBO vascular occluder is a key product. It is designed to stop blood flow in targeted areas. Okami aims to improve patient outcomes in vascular disease.
Okami's devices are intended to be user-friendly. They aim to offer versatility for various medical situations. The company's goal is to restore patient health through advanced technology.
This funding and leadership change marks a pivotal moment for Okami. They are poised for significant growth. The company seeks to improve vascular disease treatment. They will achieve this through commercial expansion. They will also develop new innovations.
The investment underscores confidence in Okami's technology. The market for vascular embolization solutions is growing. Okami is positioning itself to be a leader in this space.
The company's focus on patient outcomes is a key differentiator. Their devices are designed with both physicians and patients in mind. This patient-centric approach resonates with investors.
Okami's leadership team has a proven track record. Drew Hykes' experience at Inari Medical is invaluable. Bill Hoffman's expertise will guide the company's strategic direction.
The new board members from Gilde Healthcare bring significant experience. Their insights will help Okami navigate the medical technology landscape.
Okami's location in California's medical technology hub is advantageous. They have access to talent and resources. This supports innovation and growth.
The company's commitment to innovation is ongoing. They are developing new devices to meet evolving medical needs. This ensures they remain competitive.
Okami's growth strategy involves expanding its commercial reach. They plan to increase adoption of their LOBO platform. They also aim to broaden their product portfolio.
The $45 million funding round provides Okami with the resources. They need to execute their growth plans. They will strengthen their market position.
Okami Medical is targeting a significant unmet need in vascular care. Their technology has the potential to improve patient outcomes. It will streamline medical procedures.
The company's story is one of innovation, strategic leadership, and financial backing. This puts them on a path to success. They are poised to make a lasting impact on healthcare.
The vascular embolization market is expected to grow. This growth is driven by an aging population. There are also technological advancements. Okami Medical is well positioned to capitalize on this trend. They are solving a growing medical issue.
Okami's versatile devices are suited for a variety of vascular anatomies. This versatility gives them a competitive advantage. They can address a broader range of medical cases.
The company's focus on clinical programs demonstrates their commitment. They are dedicated to proving the effectiveness of their technology. This builds trust with physicians and patients.
The appointment of Drew Hykes as CEO is a strategic move. His experience in scaling medical device companies is invaluable. He will lead Okami through its next phase of growth.
The addition of Geoff Pardo and Susana Amorim to the board provides valuable expertise. They have a proven track record in the medical technology sector. This will guide Okami's strategic decisions.
Okami Medical's future looks bright. They are well-funded, well-led, and focused on a growing market. They will make a significant impact on vascular care.
The company's innovative solutions are transforming patient treatment. They are improving outcomes for those with vascular disease.
Okami Medical is set to become a key player in the medical device industry. They will lead innovation in vascular embolization.
"